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Abstract
Background: Thyroid cancer is the fourth most common cancer in the world. Papillary thyroid carcinoma (PTC) accounts for 80%
of all types of thyroid neoplasm. Epigenetic alterations such as DNA methylation are known as the main cause of different types of
cancers through inactivation of tumor suppressor genes.
Objectives: In the present study, the expression and methylation of suggested gene namely nucleolar protein 4 (NOL4) in PTC in
comparison to multi nodular goiter (MNG) have been studied.
Methods: Forty-one patients with PTC and 38 patients affected by MNG were recruited. Thyroid tissues were obtained during thy-
roidectomy. RNA and DNA were extracted from thyroid tissues. Quantitative RT-PCR assay was performed for determining the mRNA
level of NOL4 while methylation-sensitive high resolution methylation was applied for assessing the methylation status with design-
ing six pairs primers for six regions on gene promoter which were named from NOL4 (a) to NOL4 (f).
Results: Methylation assessment of 81 CpG islands in the promoter region of NOL4 gene revealed that NOL4 (f), the nearest region
to the start codon, was significantly hypermethylated in PTC cases compared to MNG cases. NOL4 level in PTC cases in comparison
with MNG cases were downregulated. The methylation status and mRNA level of NOL4 (f) were associated with age of diagnosis (Age
of the patient at the time of diagnosis), lymph node metastasis, and advanced stages of disease.
Conclusions: These data suggested an aberrant promoter hyper-methylation of NOL4 in PTC cases may be linked with its downreg-
ulation. Therefore, NOL4 gene can be proposed as a potential tumor suppressor gene in PTC tissues.
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1. Background
Thyroid cancer is the fourth most common can-
cer worldwide. Its incidence has increased over the
last decades. Based on the Surveillance, Epidemiol-
ogy, and End Results program (SEER) data, the number
of new cases of thyroid cancer were 52,070 and the
percentage of all new cancer cases were 3% in 2019
(http://seer.cancer.gov/statfacts/html/thyro.html). This
rate will increase to 52,890 new cases at the end of 2020 (1).
Iran Cancer Data System Registry has reported 10,913 cases
of thyroid cancer (7 - 90 years old) while the total incidence
rate (per one year) was 2.20 per 100,000, during 2004 -
2010 (2). These findings show the increased rate of thyroid
cancer in recent years. Thyroid carcinoma is classified
into four groups; papillary thyroid carcinoma, follicular
thyroid carcinoma, medullary thyroid carcinoma and
anaplastic type. papillary thyroid carcinoma is the most
common type of thyroid cancer accounting for about 80%
of thyroid neoplasms (3, 4).
B-Raf proto-oncogene serine/threonine kinase (BRAF)
mutations, especially V600E, are the most important ge-
netic factors, being responsible for different aggressive
phenotypes such as angiogenesis and tumor invasion (5).
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